Editing Lunasin

[[Information on nutritional supplements people with ALS have been taking]]

[https://en.wikipedia.org/wiki/Lunasin Wikipedia page]

*''A recent finding is that lunasin may reduce the progressive muscular weakening of ALS. Rick Bedlack, director of Duke University's ALS Clinic in Durham, NC, found a patient, Michael McDuff, who surprisingly was getting better. The cause seemed to be a regimen of lunasin that McDuff started on his own. Currently Bedlack has started a trial with other ALS patients to see if it works for a large clinically-controlled group of patients. A clinical trial is ongoing.''


== Effects on ALS ==

''found to exert potent antioxidant properties, reducing lipopolysaccharide induced production of ROS by macrophage cells, and acting as a potent free radical scavenger.'' {{#pmid:25033546|wolosik2014}}

'' The 5 kDa peptide inhibited most potently pro-inflammatory markers including interleukin-6 production (IC(50)=2 microM), interleukin-1beta production (IC(50)=13 microM), nuclear factor-kappa B (NF-kappaB) transactivation (IC(50)=21 microM), cyclooxygenase-2 expression (IC(50)=25 microM), nitric oxide production (IC(50)=28 microM), inducible nitric oxide synthase expression (IC(50)=37 microM), prostaglandin E(2) production (IC(50)=41 microM), p65 nuclear translocation (IC(50)=48 microM) and p50 nuclear translocation (IC(50)=77 microM). In conclusion, lunasin and lunasin-like peptides purified from defatted soybean flour inhibited inflammation in LPS-induced RAW 264.7 macrophage by suppressing NF-kappaB pathway.'' {{#pmid:19682518|mejia2009}}

== Where to get it from ==

[https://reliv.com/p/lunarich-x LunaRich X by Reliv]


== References ==

[[Category:Supplement data pages]]
@@ Line 3: / Line 3: @@
 [https://en.wikipedia.org/wiki/Lunasin Wikipedia page]
-*''A recent finding is that lunasin may reduce the progressive muscular weakening of ALS. Rick Bedlack, director of Duke University's ALS Clinic in Durham, NC, found a patient, Michael McDuff, who surprisingly was getting better. The cause seemed to be a regimen of lunasin that McDuff started on his own. Currently Bedlack has started a [https://clinicaltrials.gov/ct2/show/NCT02709330 trial] with other ALS patients to see if it works for a large clinically-controlled group of patients. A [https://clinicaltrials.gov/ct2/show/NCT02709330 clinical trial] is ongoing.''
+*''A recent finding is that lunasin may reduce the progressive muscular weakening of ALS. Rick Bedlack, director of Duke University's ALS Clinic in Durham, NC, found a patient, Michael McDuff, who surprisingly was getting better. The cause seemed to be a regimen of lunasin that McDuff started on his own. Currently Bedlack has started a trial with other ALS patients to see if it works for a large clinically-controlled group of patients. A clinical trial is ongoing.''
@@ Line 11: / Line 11: @@
 '' The 5 kDa peptide inhibited most potently pro-inflammatory markers including interleukin-6 production (IC(50)=2 microM), interleukin-1beta production (IC(50)=13 microM), nuclear factor-kappa B (NF-kappaB) transactivation (IC(50)=21 microM), cyclooxygenase-2 expression (IC(50)=25 microM), nitric oxide production (IC(50)=28 microM), inducible nitric oxide synthase expression (IC(50)=37 microM), prostaglandin E(2) production (IC(50)=41 microM), p65 nuclear translocation (IC(50)=48 microM) and p50 nuclear translocation (IC(50)=77 microM). In conclusion, lunasin and lunasin-like peptides purified from defatted soybean flour inhibited inflammation in LPS-induced RAW 264.7 macrophage by suppressing NF-kappaB pathway.'' {{#pmid:19682518|mejia2009}}
-''Extensive scientific studies have shown that lunasin possesses inherent antioxidative, anti-inflammatory, anticancerous properties and could also play a vital role in regulating of cholesterol biosynthesis in the body. Its high bioavailability and heat stable nature allow its potential use as dietary supplement.'' {{#pmid:25627564|lule2015}}
-''The amaranth lunasin-like peptide, however, requires less time than the soybean lunasin to internalize into the nucleus of NIH-3T3 cells, and inhibits histone acetylation (H(3) and H(4) in a 70 and 77%, respectively). The amaranth lunasin-like peptide inhibited the transformation of NIH-3T3 cells to cancerous foci. The open reading frame (ORF) of amaranth lunasin corresponds to a bifunctional inhibitor/lipid-transfer protein (LTP). LTPs are a family of proteins that in plants are implicated in different functions, albeit all linked to developmental processes and biotic and abiotic stress resistance.'' {{#pmid:20599579|maldonado2010}}
-== ALSUntangled report on Lunasin ==
-[http://www.tandfonline.com/doi/pdf/10.3109/21678421.2014.959297 ALSUntangled No. 26: Lunasin] (23.9.2014):
-*''Lunasin has interesting mechanisms of action that might be useful in treating ALS, and it appears reasonably safe although some forms of it are expensive. While some PALS have reported improvements on lunasin, we have thus far found only one in which we were able to independently validate these improvements. This patient had atypical features for ALS including a history of myasthenia gravis, which can produce weakness that improves spontaneously. At this time there is not enough evidence to recommend that PALS take lunasin. A reasonable next step would be a small pilot trial of lunasin with validated ALS diagnoses and outcome measures.''
 == Where to get it from ==
 [https://reliv.com/p/lunarich-x LunaRich X by Reliv]
 == References ==
 [[Category:Supplement data pages]]